Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talazoparib in Japanese patients with advanced solid tumors
NCT03343054Phase 1Completed
- Sponsor
- Pfizer
- Start
- Nov 2017
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of talazoparib in solid tumor and breast cancer, sponsored by Pfizer. Primary endpoints: Dose-Limiting Toxicities and Objective Response Rate up to 502 days. Started Nov 2017; status: completed.
02
Drugs
talazoparib
03
Conditions
solid tumorbreast cancer
Beyond the preview
Go deeper on NCT03343054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03343054.